Imunon, Inc. Revenue from Contract with Customer, Including Assessed Tax
Imunon, Inc. (IMNN) reported Revenue from Contract with Customer, Including Assessed Tax of $125.00 thousand for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-11.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2018-05-11
- Imunon, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2018-03-31 was $125.00K, a 0.00% change year-over-year.
- Imunon, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2017-03-31 was $125.00K.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month |
|---|---|
| 2018-03-31 | $125.00K 10-Q · filed 2018-05-11 |
| 2017-03-31 | $125.00K 10-Q · filed 2018-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |